GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in ASCO Study

New observational data presented at ASCO 2026 explores a potential link between GLP-1 drugs and cancer progression.

New Observational Data Presented at ASCO 2026

Exciting new data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggests that GLP-1 receptor agonists (medications widely used for weight care and diabetes) may play a role in slowing down cancer progression. The real-world analysis found that patients using these medications had a significantly lower rate of cancer spreading (metastasizing) to other parts of the body. While these findings are retrospective and observational, they mark a vital step forward in understanding the broader health benefits of metabolic therapies.

Because the study is not yet published in a peer-reviewed journal, experts caution that it cannot prove GLP-1 drugs directly cause this risk reduction. Researchers will need to conduct randomized, prospective clinical trials to confirm these promising early results.

What the Study Found

According to ASCO Abstract 3510, researchers analyzed the health records of over 10,000 patients with stage I–III cancer using the TriNetX global database. They matched GLP-1 users against a control group taking DPP-4 inhibitors (gliptins), ensuring both groups had similar BMIs, smoking histories, and cancer treatments. The study tracked seven obesity-related cancers and revealed that GLP-1 users experienced a significantly lower risk of progressing to stage IV metastatic disease:

• Non-small cell lung cancer (NSCLC): Experienced a 50% lower risk of metastatic progression.
• Breast adenocarcinoma: Experienced a 43% lower risk.
• Hepatocellular carcinoma (liver cancer): Experienced a 38% lower risk.
• Colorectal adenocarcinoma: Experienced a 31% lower risk.

While prostate, kidney, and pancreatic cancers also showed fewer metastatic events in the GLP-1 group, those specific trends did not reach statistical significance. Still, the overall trend suggests a positive impact across multiple tumor types.

Exploring a Potential Biological Mechanism

To find out why this happens, the research team analyzed tumor data from The Cancer Genome Atlas. They discovered that patients whose tumors expressed high levels of the GLP-1 receptor had a 33% lower risk of death across all seven cancer types. In breast cancer specifically, high receptor expression was linked to a 45% reduction in mortality risk, suggesting the drug might act directly on cancer cells.

However, cancer specialists like Dr. Monica Avila of the Moffitt Cancer Center point out that it is still unclear whether the drug directly alters tumor biology or if the benefit comes from improved metabolic health and weight loss. For patients curious about these treatments, consulting a clinician about semaglutide treatment programs can help clarify how metabolic health affects overall disease resistance.

Safety Observations and Limitations

The study reported that patients using GLP-1 drugs did not experience any increase in serious adverse events like pancreatitis or stomach inflammation compared to the control group. The safety profile remained consistent with what is already known about these medications. However, oncologists emphasize that several limitations must be considered:

• The study is retrospective, meaning it can only find associations, not prove cause-and-effect.
• Even with rigorous matching, other variables like diet or exercise could influence the results.
• DPP-4 inhibitors used by the control group have their own biological effects, which could affect the comparison.
• The findings are still preliminary and have not yet undergone the formal peer-review process.

What This May Mean Going Forward

Oncologists and researchers are calling for clinical trials to study whether GLP-1 receptor agonists can be integrated into standard cancer care plans. These preliminary findings build on a growing list of research showing that metabolic health is deeply connected to cancer survival. By improving how the body manages glucose and inflammation, GLP-1 therapies may help create an environment where cancer is less likely to spread.

If you are currently taking a GLP-1 drug, you should not make any changes to your treatment plan based on these preliminary findings. Always discuss your medication, cancer risk, and long-term health goals directly with your oncologist or primary care provider.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.